MEDI-IMMUNE - Key Persons


James Love

Job Titles:
  • Director
Director - James Love, is a chartered mechanical engineer, who graduated from Imperial College London. He is an innovative engineer, and problem solver, whose recent focus has been on medical device concept design and medical device regulatory compliance.

John James

Job Titles:
  • Director
Director - John James has a long history of innovation and creative design and the development of software systems and applications for use in different sectors including pharmaceutical, defence, electronic and medical. His recent focus has been on the creation and application of UVc in devices, in the medical sector.

John Maudsley

Job Titles:
  • Director
Director - John Maudsley is an immunologist with a BSc and PhD from University College London. He spent some years in immunology research at Warwick University, within the Virus Group. His focus over many years has been on the development of cancer vaccines.

John Willcocks


Tim Bretherick

Job Titles:
  • Consultant
Consultant - Tim Bretherick qualified as an accountant with MAB. For many years he has been running his own successful consulting business specialising in all aspects of Facilities Management. Tim came on board as an investor to support the development of a novel concept. qualified as an accountant with MAB. For many years he has been running his own successful consulting business specialising in all aspects of Facilities Management. Tim came on board as an investor to support the development of a novel concept. Director - John Willcocks' early career was in major IT companies and since 1982 he has run his own businesses, working within blue chip organisations, around the globe, delivering management development programmes. He is a skilled communicator at all levels. Director - Robert Foley graduated from Essex University, with an MSc in pure and applied mathematics. He now lives in the United States, having moved there when working for GE. He built up his own computer service company, which he sold very successfully in 2007, remaining CEO until 2009. He is now a private investor.